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O B J E C T I V E S The objective of this substudy of the ASTRONOMER (Aortic Stenosis Progression
Observation: Measuring Effects of Rosuvastatin) trial was to examine the association between insulin
resistance and progression of left ventricular hypertrophy (LVH) in patients with aortic stenosis (AS).
B A C KG ROUND In a recent cross-sectional study, the authors reported that the metabolic
syndrome was associated with an increased prevalence of concentric LVH in patients with AS. As a
central feature of the metabolic syndrome, insulin resistance could be an important mediator of this
association.
METHOD S This substudy included 250 of 269 patients enrolled in ASTRONOMER. Follow-up was
3.4 1.3 years. Insulin resistance was evaluated using the homeostatic assessment model (HOMA) index,
and patients were dichotomized using the median HOMA index value (1.24). The rate of LVH progression
was estimated by calculating the annualized change in LV mass index (LVMi), measured on echocardi-
ography. The presence of LVH was deﬁned as an LVMi 47 g/m2.7 in women and 49 g/m2.7 in men.
R E S U L T S There was a signiﬁcant progression of LVH among the patients without LVH at baseline
(n  134; p  0.0001) but not in those with it (n  116; p  NS). In those without LVH at baseline, the
annualized progression rate of LVMi was signiﬁcantly faster in the subset with HOMA 1.24 compared
to that in the subset with HOMA 1.24 (2.49  4.38 g/m2.7/year vs. 0.03  3.90 g/m2.7/year; p 
0.001). During follow-up, LVH developed in 46% of patients with HOMA 1.24 compared to 11% of
those with HOMA 1.24 (p  0.0005). Independent predictors of faster LVH progression identiﬁed on
multivariate analysis were history of hypertension (p  0.048), degree of aortic valve calciﬁcation (p 
0.035), and HOMA index (p  0.02).
CONC L U S I O N S In this ASTRONOMER substudy, insulin resistance was a powerful independent
predictor of progression to LVH in patients with AS. Visceral obesity and ensuing insulin resistance may
thus present novel therapeutic targets in AS patients. (J Am Coll Cardiol Img 2013;6:165–74) © 2013 by
the American College of Cardiology Foundation
From the *Institut Universitaire de Cardiologie et de Pneumologie de Québec/Québec Heart & Lung Institute, Laval
University, Québec, Québec, Canada; †University of Ottawa Heart Institute, Ottawa, Ontario, Canada; ‡McMaster University,
Hamilton, Ontario, Canada; and the §St. Boniface General Hospital, Winnipeg, Manitoba, Canada. The ASTRONOMER
study was funded by AstraZeneca and the Canadian Institutes of Health Research (CIHR), Ottawa, Canada. This
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he pressure overload associated with aor-
tic stenosis (AS) as well as with concomitant
systemic arterial hypertension may lead to
the development of left ventricular hyper-
rophy (LVH). LVH has been linked to occur-
ence of LV dysfunction, an increased risk for
ardiac events, and a higher operative risk for
ortic valve replacement in the AS population
1–5). Besides the pressure overload caused by
alvular obstruction and concomitant arterial hy-
ertension, the other factors influencing the de-
elopment and progression of LVH in AS pa-
ients are unknown.
Visceral obesity is associated with a cluster of
etabolic abnormalities often referred to as the
etabolic syndrome (MetS), including insulin resis-
ance, atherogenic dyslipidemia, and pro-
nflammatory state (6). Although visceral fat accu-
ulation may be causally related to the features of
insulin resistance, it may also be a marker
of dysfunctional adipose tissue resulting
from a sedentary lifestyle and excessive
calorie consumption (6). Previous studies
suggest that this dysmetabolic state is asso-
ciated with an increased prevalence of aortic
valve calcification (7), faster progression rate
of AS (8,9), and increased arterial stiffness
(10). In a recent cross-sectional substudy of the
ASTRONOMER (Aortic Stenosis Progres-
sion Observation: Measuring Effects of Rosu-
vastatin) trial, which enrolled patients with
mild to moderate AS, the authors reported
that MetS was independently associated
with a higher prevalence of concentric
LVH and impairment of LV systolic func-
ion, even after adjustment for global LV pressure
verload (11). In the SEAS (Simvastatin Ezetimibe
n Aortic Stenosis) trial, greater body mass index
BMI) was associated with the presence of LVH in
atients with asymptomatic AS, independent of AS
everity and the presence of hypertension (12).
ore recently, Lindman et al. (13) reported an
ssociation between type 2 diabetes and LVH and
V dysfunction in patients with severe AS referred
substudy was also funded in part by a CIHR grant #MOP-79342. M
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re
nceManuscript received May 30, 2012; revised manuscript received November 1or aortic valve replacement. These findings lend
upport to the hypotheses that: 1) in AS patients,
he dysmetabolic state associated with visceral obe-
ity may pre-dispose to the development of LVH
ndependently of global (i.e., valvular and arterial)
emodynamic load; and 2) insulin resistance could
e a key mediator of this association. The objective
f this substudy of the ASTRONOMER trial was
o test the hypothesis that insulin resistance is
elated to the progression of LVH and global LV
emodynamic load.
M E T H O D S
The protocol and results of the ASTRONOMER
trial have been extensively described elsewhere (14).
Patient population. Between 2002 and 2005, 269
atients with mild to moderate AS were enrolled
nto the ASTRONOMER trial at 23 Canadian
ites. Patients between 18 and 82 years of age and
aving a peak aortic jet velocity between 2.5 and 4.0
/s were included. Patients with severe or symp-
omatic AS, severe aortic regurgitation, mitral valve
isease (mitral stenosis or greater than mild mitral
egurgitation), symptomatic coronary artery disease,
ongestive heart failure, diabetes, or a need for
holesterol-lowering treatment were excluded. Pa-
ients were randomly assigned to receive rosuvastatin
0 mg or placebo. For the purpose of this pre-
pecified substudy, clinical, laboratory, and Doppler
chocardiography data were collected and analyzed
n 250 of the 269 patients (93%) recruited in the
STRONOMER trial. Nineteen patients (7%) were
xcluded from this substudy because Doppler echo-
ardiography follow-up data were not available. The
ean follow-up time was 3.4  1.3 years.
Clinical and laboratory data. Clinical data included
ge, sex, weight, height, BMI, waist circumference,
moking history, documented diagnosis of hyper-
ension (blood pressure 130/85 mm Hg and/or
eceiving antihypertensive medication), and ran-
omization group (statin or placebo).
Fasting blood samples were collected at the
aseline and last follow-up visits to determine
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167glucose, insulin, and creatinine concentrations and a
complete lipid profile, which included total choles-
terol, triglycerides, low-density lipoprotein choles-
terol, high-density lipoprotein cholesterol, and apo-
lipoprotein B, using automated techniques
standardized with the Canadian reference labora-
tory. To assess insulin resistance, the homeostatic
assessment model (HOMA) index (15) was calcu-
lated using fasting glucose and insulin levels and the
following formula: insulin (in U/ml)  (glucose
[in mmol/l]/22.5).
Doppler echocardiography data. AORTIC VALVE
ORPHOLOGY AND FUNCTION. The Doppler
chocardiography indexes of AS severity included
eak aortic jet velocity; peak and mean transvalvular
ressure gradients, obtained with the use of the
odified Bernoulli equation; and the aortic valve
rea, calculated by the standard continuity equation.
he degree of aortic valve calcification was scored
ccording to the criteria proposed by Rosenhek
t al. (16).
LV GEOMETRY AND FUNCTION. LV minor axis in-
ternal dimension (LVID), posterior wall thickness
(PWT), and interventricular septal thickness
(IVST) were measured according to the recommen-
dations of the American Society of Echocardiogra-
phy (17). Relative wall thickness (RWT) was cal-
culated as (PWT  IVST)/LVID. The corrected
formula of the American Society of Echocardiog-
raphy was used to calculate LV mass, which was
indexed to a 2.7 power of height (LVMi) (18).
LVH was defined as LVMi49 g/m2.7 in men and
47 g/m2.7 in women (18).
By taking into account both LVMi and RWT,
atients were classified as having 1 of 4 LV remod-
ling patterns, using the following criteria suggested
y Cramariuc et al. (2): 1) normal pattern: absence
f LVH and RWT 0.43; 2) concentric remodel-
ng: absence of LVH and RWT 0.43; 3) concen-
ric hypertrophy: presence of LVH and RWT
0.43; and 4) eccentric hypertrophy: presence of
VH and RWT 0.43. LV ejection fraction was
easured with the use of the biplane Simpson
ethod.
GLOBAL LV HEMODYNAMIC LOAD. As a measure
f global LV hemodynamic load, valvuloarterial
mpedance (Zva) was calculated as (SBP 
Pmean)/SVi, where SBP is systolic blood pres-
sure, Pmean is the mean transvalvular gradient,
nd SVi is the stroke volume indexed to a 2.04
ower of height (11).Study outcomes. The primary outcome of this study
was LVH progression, measured as the change
from baseline in LVMi during follow-up. To ac-
count for varying durations of follow-up, change in
LVMi was annualized by dividing the total change
in LVMi by the duration of follow-up. The sec-
ondary end points were changes from baseline in
severity of AS and global LV hemodynamic load,
assessed by annualized changes in peak aortic jet
velocity and Zva, respectively. We also assessed the
effect of rosuvastatin on these end points.
Statistical analysis. Continuous data are expressed as
mean  SD and were compared using the Student
t test. Categorical data are expressed as percentages
and were compared using the chi-square or Fisher
exact test as appropriate. According to the pre-
specified analysis plan, the patients were dichoto-
mized on the basis of the median HOMA index
value (i.e., 1.24 in this series). Multivariate linear
regression analysis was performed to identify inde-
pendent predictors of the primary and secondary
study outcomes: progression to LVH and hemody-
namic load. Variables entered into the multivariate
model were: 1) all variables with a p value0.10 on
individual analysis; and 2) clinically relevant vari-
ables (i.e., age, male, creatinine level, and baseline
LVMi) regardless of p value. Standardized raw-
score regression coefficients (i.e., ) are presented.
Logistic generalized linear mixed modeling using
multinomial distribution for the response variable
was performed to identify predictors of worsening
LV patterns. All mixed models were adjusted for
duration of follow-up. A subsequent adjustment for
randomization status was performed in the mixed
and multivariate models. A p value 0.05 was
considered statistically significant.
R E S U L T S
Progression of LV hypertrophy. Among the 250 pa-
tients included in this substudy, 134 (54%) had no
significant LVH at baseline, and 116 patients (46%)
presented LVH, among whom 73 (63%) had con-
centric hypertrophy. The group without LVH at
baseline had a significant increase in LVMi from
baseline to last follow-up (37.8  6.4 g/m2.7 vs.
42.9  10.2 g/m2.7; p  0.0001), whereas the
change in LVMi from baseline to follow-up was
nonsignificant in the group with LVH at baseline
(61.0  10.8 g/m2.7 vs. 58.9  14.4 g/m2.7; p 
NS). The prevalences of MetS (37% vs. 19%; p 
0.002) and hypertension (48% vs. 19%; p 
0.0001), as well as the HOMA index (2.2  1.7 vs.
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1681.7  1.4; p  0.02), were significantly higher in
he group with LVH at baseline compared to the
roup without it (Online Table). However, the
everity of AS and the Zva were similar in the 2
groups. The durations of follow-up were similar in
the 2 groups (no LVH: 3.5  1.3 years; LVH:
3.3  1.3 years.
There was a significant interaction between base-
line HOMA index and baseline LVMi with regard
to the effect on LVH progression (i.e., annualized
change in LVMi) during follow-up (p  0.04). No
significant association was found between HOMA
index and LVH progression in patients with LVH
at baseline (p  0.23), whereas HOMA index was
a significant predictor of progression of LVH in
patients without LVH at baseline (p  0.0003).
Hence, most of the analyses presented in this paper
focus on the group of patients without LVH at
baseline (n  134).
After dichotomization according to the median
value of HOMA index in the group of patients
without LVH at baseline, the subset with a HOMA
index 1.24 was found to have a greater BMI and
waist circumference; higher prevalence of smoking
history; higher prevalence of MetS; lower preva-
lence of bicuspid aortic valve phenotype; higher
plasma levels of triglycerides, fasting glucose, fast-
ing insulin, and creatinine; and a lower plasma level
of high-density lipoprotein cholesterol compared to
the subset with a HOMA index 1.24 (Table 1).
Numerical but statistically nonsignificant differ-
ences in the following parameters were also found
in the subset with HOMA index 1.24: older age,
greater baseline LVMi, higher prevalence of hyper-
tension, higher SBP, and higher plasma level of
low-density lipoprotein cholesterol. Baseline Dopp-
ler echocardiography data showed similar AS sever-
ity, Zva, and LV ejection fraction values in the 2
roups. The durations of follow-up were similar in
he subset with a HOMA index 1.24 and the
ubset with a HOMA index1.24 (3.4 1.3 years
s. 3.6  1.2 years; p  NS).
During follow-up, LVH developed in 46% of
atients with a HOMA index 1.24 compared to
1% in patients with a HOMA index 1.24 (p 
0.0005). On analysis of change in the LV remod-
eling pattern during follow-up, the group with a
HOMA index 1.24 had significant worsening of
LV geometry during follow-up (p  0.003),
hereas the group with a HOMA index 1.24 did
ot (Fig. 1).
Progression of LVH was significantly faster inhe group with a HOMA index1.24 compared tothe group with a HOMA index 1.24 (annualized
change in LVMi: 2.49  4.38 g/m2.7/year vs.
0.03  3.90 g/m2.7/year; p  0.001) (Fig. 2A).
Other baseline variables associated with faster LVH
progression on univariate analysis were BMI (p 
0.001), history of hypertension (p  0.008), degree
f aortic valve calcification (p  0.004), and peak
ortic jet velocity (p  0.03) (Table 2). After
adjustment for these variables as well as other
clinically relevant variables (i.e., age, male sex,
creatinine level, and baseline LVMi), independent
predictors of faster LVH progression were a history
of hypertension (p  0.048), degree of aortic valve
alcification (p  0.035), and HOMA index (p 
.02) (Table 2, multivariate model 1). After addi-
ional adjustment for baseline SBP and global LV
emodynamic load (i.e., Zva), the predictors of
LVH progression were degree of aortic valve calci-
fication (p 0.031) and HOMA index (p 0.015)
(Table 2, multivariate model 2).
Progression of AS and global LV hemodynamic load.
Higher HOMA index was significantly associated
with faster progression of AS (i.e., annualized
change in peak aortic jet velocity: r  0.17; p 
0.05). HOMA index was also associated with in-
creased global LV hemodynamic load (i.e., annual-
ized change in Zva) in the group without LVH at
aseline (r  0.21; p  0.045), but not in the
verall cohort (p  0.80) or in the group with
re-existing LVH (p  0.38). Lower SBP (r 
0.25; p  0.01) and lower Zva (r  0.38; p 
.0001) at baseline were also associated with greater
rogression of Zva during follow-up. On multivar-
ate analysis that included these variables as well as
ge, sex, and peak aortic jet velocity, HOMA index
emained an independent predictor of Zva progres-
sion rate in the subset of patients without LVH
(p  0.003) (Table 3).
Given that the HOMA index was associated
with faster progression of AS and Zva, additional
ultivariate models were examined for progression
f LVH, with further adjustment for the annualized
hanges in peak aortic jet velocity and SBP (Table 2,
ultivariate model 3) and for annualized change in
va (Table 2, multivariate model 4). In these
odels, HOMA index remained independently
ssociated with faster progression of LVH.
Effects of statin therapy. Among the patients treated
with rosuvastatin, the progression of LVH was
significantly faster in the subgroup with a HOMA
index 1.24 compared to that with a HOMA
index 1.24 (annualized change in LVMi: 3.26 
5.17 g/m2.7/year vs. 0.06  2.28 g/m2.7/year; p 
Ht
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1690.003), whereas the difference between these 2
subgroups did not reach statistical significance in
the patients receiving placebo (1.74  3.36 g/m2.7/
year vs. 0.12  5.03 g/m2.7/year; p  0.09).
Table 1. Baseline Characteristics of the Study Patients Without
Patients Without L
at Baseline (n  1
Clinical
Age, yrs 56 13
Male 56
Height, cm 170 9
Weight, kg 77 18
Body surface area, m2 1.88 0.23
Body mass index, kg/m2 26.5 5.5
Waist circumference, cm 91 14
History of hypertension 19
Systolic blood pressure, mm Hg 124 17
Diastolic blood pressure, mm Hg 75 11
History of smoking 44
Metabolic syndrome 19
Medication
Antihypertensive treatment 15
ACE inhibitor 8
ARB 7
Rosuvastatin 49
Laboratory data
LDL cholesterol, mg/dl 124 29
ApoB, mg/dl 100 20
HDL cholesterol, mg/dl 60 18
Triglycerides, mg/dl 118 61
Fasting glucose, mg/dl 94 12
Fasting insulin, U/ml 7.8 5.5
HOMA index 1.7 1.4
Creatinine, mg/dl 0.90 0.18
Doppler echocardiography data
Bicuspid aortic valve 51
Aortic valve calciﬁcation score 1.6 0.7
Peak aortic jet velocity, m/s 3.14 0.39
Peak transvalvular gradient, mm Hg 40 10
Mean transvalvular gradient, mm Hg 22 7
Aortic valve area, cm2 1.30 0.40
Indexed aortic valve area, cm2/m2 0.70 0.20
Valvuloarterial imped., mm Hg/ml/m2.04 4.9 1.5
LV end-diastolic diameter, mm 47.2 5.8
Interventricular septal thickness, mm 9.8 1.7
Posterior wall thickness, mm 9.5 1.3
Relative wall thickness ratio 0.42 0.09
LV mass index, g/m2.7 37.8 6.4
Left ventricular ejection fraction 66 6
Values are mean  SD or %.
ACE angiotensin-converting enzyme; apoB apolipoprotein B; ARB angiot
lipoprotein; LV  left ventricle; LVH  left ventricular hypertrophy.owever, there was no significant difference be- oween the statin and placebo arms in the overall
tudy group or within each HOMA index subgroup
ith respect to the progression of LVH (1.24:
 0.86; 1.24: p  0.18) (Fig. 2B). When status
at Baseline
HOMA Index <1.24
(n  67)
HOMA Index >1.24
(n  67) p Value
54 11 58 13 0.09
49 63 NS
168 10 171 10 0.07
69 11 84 17 0.0001
1.78 0.18 1.96 0.24 0.0001
24.3 3.1 28.4 4.6 0.0001
84 11 95 12 0.0001
13 25 0.08
121 15 127 20 0.06
76 12 74 10 NS
33 52 0.04
5 33 0.0001
6 20 0.02
3 12 0.051
3 8 NS
51 50 NS
119 30 128 28 0.08
97 21 103 19 NS
66 21 53 14 0.0001
104 56 130 63 0.01
90 7 98 14 0.0001
3.9 0.9 10.3 5.8 0.0001
0.8 0.2 2.5 1.5 0.0001
0.85 0.14 0.93 0.21 0.03
70 34 0.0001
1.6 0.7 1.7 0.6 NS
3.15 0.41 3.09 0.35 NS
40 11 39 9 NS
23 7 21 6 NS
1.27 0.43 1.34 0.38 NS
0.72 0.22 0.69 0.19 NS
4.7 1.1 5.1 1.8 NS
46.8 5.9 47.4 5.6 NS
9.6 1.4 10.2 1.8 0.03
9.2 1.2 9.9 1.3 0.004
0.41 0.08 0.43 0.09 NS
36.8 6.6 39.0 6.0 0.052
65 6 66 6 NS
n receptor blocker; HOMA homeostatic assessment model; LDL low-densityLVH
VH
34)
ensif randomization was added into the multivariate
tric
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170models, HOMA index remained significantly asso-
ciated with faster progression of LVH (p  0.018)
and worsening LV geometry (p  0.008), whereas
statin therapy was not a significant predictor.
D I S C U S S I O N
This is the first prospective study, to our knowl-
edge, to report that insulin resistance is a powerful
independent predictor of faster progression of LVH
in patients with AS. This detrimental contribution
of insulin resistance to changes in LV mass and
geometry persisted even after the adjustment for the
baseline AS severity and global LV hemodynamic
load, their progression over time, and the status of
randomization.
In patients with AS, LVH compensates for
pressure overload. However, the presence and mag-
nitude of LVH is highly variable from one patient
to another. Excessive LV concentric remodeling or
hypertrophy has been linked to poorer myocardial
function, faster progression to symptoms, and in-
creased operative and late mortality rates after aortic
valve replacement (1–5).
In a recent cross-sectional substudy of the
ASTRONOMER trial, the authors reported that,
p=NS
p=NS
1
No Hypertrophy: Conc. Rem.
HOMA<1.24
0
20
40
60
80
100
Baseline Follow-up
Normal
Figure 1. Prevalence of LV Remodeling Patterns in Patients Wit
Comparison of left ventricular (LV) remodeling patterns at baseline
model (HOMA) index 1.24 versus those with a HOMA index 1.24
remodeling; Eccen. Hypert.  eccentric hypertrophy; LVH  left vennotwithstanding AS severity and magnitude ofglobal LV hemodynamic load (i.e., Zva), MetS was
independently associated with more pronounced
concentric LVH in patients with mild to moderate
AS. In the present longitudinal study, insulin resis-
tance, which is a central feature of visceral obesity,
MetS, and diabetes, predicted faster progression of
LVH and global LV hemodynamic load. Insulin
resistance may worsen LV remodeling and function
by several mechanisms. First, it may promote myo-
cardial hypertrophy and fibrosis through several
signaling pathways, including Akt, transforming
growth factor , and peroxisome proliferator-
activated receptor (19). Second, insulin resistance is
associated with several alterations in plasma sub-
strates of myocardial metabolism, mainly increased
free fatty acid (FFA) and glucose levels (20). In the
myocardium exposed to pressure overload related to
AS and/or concomitant systemic hypertension,
FFA oxidation is reduced, and insulin resistance
may further enhance FFA supply and thereby
worsen the accumulation of triglycerides within the
myocytes (21,22). The resulting lipotoxicity may
predispose to hypertrophy, dysfunction, and apop-
tosis of myocytes. In this regard, studies in animals
(21,23) have reported that the dysregulation of FFA
p=0.0005
p=0.003
46%
Hypertrophy: Conc. Hypert.
HOMA>1.24
Baseline Follow-up
Eccen. Hypert.
t LVH at Baseline (N  134)
last follow-up visits in patients with a homeostatic assessment
nc. Hypert.  concentric hypertrophy; Conc. Rem.  concentric
ular hypertrophy.1%
hou
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171fat diet worsens LVH induced by aorta constriction.
In these models, there was a synergistic interaction
between the hemodynamic load and the metabolic
condition (i.e., LV mass was increased to a greater
extent in the animals fed the high-carbohydrate,
high-fat diet compared to those fed a normal diet). In
the present study, the association between insulin
resistance and faster progression of LVH persisted
even after adjustment for the global (i.e., valvular and
arterial) LV hemodynamic load and its progression
over time. These findings suggest that, in AS patients,
the contribution of insulin resistance to the progres-
sion of LVH is, at least in part, independent of
pressure overload. However, further studies are
needed to determine whether this metabolic-
hemodynamic stress interaction is simply additive
or synergistic.
Insulin resistance was associated with a more
pronounced increase in the prevalence of LV con-
centric remodeling and hypertrophy. This may, in
turn, increase the risk for paradoxical low-flow AS,
a clinical entity recently described by Hachicha et
al. (24). Paradoxical low-flow AS is characterized
by exaggerated LV concentric remodeling, small
LV cavity size with impaired filling, increased
myocardial fibrosis, and reduced stroke volume
despite preserved LV ejection fraction (25).
Effects of statins. In a recent substudy of the
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Figure 2. Annualized Progression Rate of Indexed LV Mass in P
Comparison of patients with a HOMA index 1.24 versus those wit
zation according to randomization status (statin [triangles] vs. plac
HOMA 1.24; †p  0.05 versus placebo–HOMA 1.24. HOMA  h
LVMi  left ventricular mass index.STRONOMER trial (9), statin therapy was as- cociated with a deterioration of patients’ insulin
esistance, and this effect was more pronounced in
hose patients with MetS. In this latter subset,
tatin therapy was also associated with faster pro-
ression of AS severity; however, on multivariate
nalysis, there was no significant independent contri-
ution of statin therapy and no significant association
etween MetS and statin use. In the present study,
atients with evidence of insulin resistance as reflected
y a high HOMA index and treated with a statin had
he fastest progression of LVH. However, there was
o significant difference between the statin and pla-
ebo arms in the overall group or in either of the 2
OMA index groups. The apparent faster progres-
ion of stenosis and LVH in the subset of normocho-
esterolemic patients with MetS who received the
tatin thus needs to be confirmed in future studies.
Clinical implications. In light of the previous studies
8,9,11,13) and of the present work, the metabolic
bnormalities linked to visceral obesity, and in
articular insulin resistance, may accelerate the
eterioration of the structure and function, not only
f the aortic valve and arteries, but also of the left
entricle, which may, in turn, yield to an increased
isk for cardiac events. These findings thus under-
ine the importance of identifying viscerally obese
atients and assessing the degree of insulin resis-
ance in the AS population. Aggressive lifestyle
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nts Without LVH at Baseline (N  134)
HOMA index 1.24 in the overall group (A), and after dichotomi-
[circles]) (B). Error bars represent SEM. *p  0.05 versus statin–
ostatic assessment model; LVH  left ventricular hypertrophy;atie
h a
ebo
omehanges such as increased physical activity and
Table 2. Predictors of LV Mass Progression in Patients Without LVH at Baseline (N  134)
Univariate Model
Multivariate Models*
1 2 3 4
 p Value  p Value  p Value  p Value  p Value
Baseline variables
Age, yrs 0.12 0.003 0.17 –0.06 0.003 0.59 –0.03 0.003 0.57 0.03 0.003 0.69 –0.03 0.003 0.88
Male 0.02 0.03 0.60 0.03 0.04 0.57 0.03 0.04 0.55 0.04 0.05 0.45 0.07 0.04 0.24
Body mass index, kg/m2 0.28 0.006 0.001 0.14 0.009 0.23 0.13 0.01 0.29 0.14 0.009 0.25 0.16 0.01 0.20
History of hypertension 0.12 0.03 0.008 0.09 0.04 0.048 0.07 0.05 0.15 0.04 0.05 0.44 0.08 0.05 0.16
Systolic blood pressure, mm Hg 0.16 0.002 0.11 — — 0.08 0.003 0.38 0.12 0.003 0.25 0.04 0.003 0.64
History of smoking 0.12 0.03 0.09 0.04 0.03 0.58 0.03 0.03 0.64 0.002 0.03 0.98 0.01 0.04 0.83
Creatinine, mol/l 0.04 0.003 0.69 0.18 0.003 0.09 0.22 0.003 0.10 0.22 0.003 0.06 0.29 0.003 0.034
HOMA index 0.32 0.02 0.0003 0.25 0.03 0.02 0.27 0.03 0.015 0.24 0.03 0.02 0.24 0.03 0.040
Aortic valve calciﬁcation score 3 0.13 0.03 0.004 0.10 0.04 0.035 0.10 0.04 0.031 0.08 0.04 0.09 0.05 0.04 0.35
Peak aortic jet velocity, m/s 0.19 0.09 0.03 0.10 0.09 0.23 0.08 0.09 0.36 0.02 0.09 0.87 0.04 0.10 0.72
Valvuloarterial impedance,
mm Hg/ml/m2.04
0.03 0.02 0.74 — — 0.06 0.03 0.52 0.07 0.02 0.44 0.03 0.03 0.83
LV mass index, g/m2.7 0.04 0.005 0.65 0.11 0.004 0.18 0.16 0.006 0.10 0.17 0.006 0.07 0.14 0.006 0.15
Follow-up variables
Annualized peak aortic jet velocity,
m/s/yr
0.15 0.12 0.10 — — — — 0.4 0.19 0.37 — —
Annualized systolic blood pressure,
mm Hg/yr
0.19 0.003 0.03 — — — — 0.23 0.004 0.043 — —
Annualized valvuloarterial
impedance, mm Hg/ml/m2.04/yr
0.11 0.08 0.28 — — — — — — 0.11 0.09 0.32
 Values are standardized raw-score regression coefﬁcients  SE. *Model 1 was adjusted for variables that were signiﬁcantly associated with the progression of LVH on univariate analysis and other clinically relevant variables (i.e., age, sex, creatinine
level, and baseline LVMi), regardless of their statistical signiﬁcance; model 2 was model 1  adjustment for systolic blood pressure and valvuloarterial impedance; model 3 was model 2  adjustment for annualized changes in peak aortic jet velocity
and systolic blood pressure; model 4 was model 2  adjustment for annualized progression of valvuloarterial impedance.
LVH  left ventricular hypertrophy; LVMi  indexed left ventricular mass; other abbreviations as in Table 1.
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173dietary changes aimed at weight loss should be
implemented in patients with a higher HOMA
index and/or with a diagnosis of MetS or type 2
diabetes (6). Unfortunately, long-term compliance
with lifestyle changes is difficult to achieve, and
specific pharmacologic therapies directed toward an
improvement in insulin sensitivity will have to be
assessed in future studies. Furthermore, patients
with a high HOMA index, MetS, and/or diabetes
should receive close clinical and echocardiographic
follow-up, given that they are at a higher risk for
fast progression of valve stenosis, increased global
LV hemodynamic load, and LVH.
Study limitations. Although patients with pre-existing
VH had poorer metabolic profiles and a higher
revalence of hypertension at baseline compared to
hose with no LVH, they nonetheless had no signif-
cant progression of LVH during follow-up and no
ignificant association was found with HOMA index.
hese findings may be related to the following factors:
) patients with a normal LV mass at baseline likely
ave a greater potential for LVH progression than do
hose with pre-existing LVH; and 2) the inability to
etect statistically significant progression of LVH as well
s a significant association with HOMA index in the
ubset of patients with pre-existing LVH may have been
ue to the interobserver/intraobserver variability in the
easurement of LVMi, which has been reported to be
igher in patients with greater LV mass (26).
In view of the relatively small number of patients
ncluded in this study, some subanalyses have lim-
ted statistical power. In particular, the lack of a
tatistically significant difference in LVMi between
atients treated with statin versus those with pla-
ebo in the subgroup with HOMA 1.24 (p 
.18) may have been due to a type II error.
Given that the need for statin therapy was a pre-
Table 3. Predictors of Valvuloarterial Impedance Progression in
Variable
Un

Age, yrs 0.02 0.00
Male 0.03 0.00
Systolic blood pressure, mm Hg 0.15 0.00
HOMA index 0.13 0.00
Aortic valve calciﬁcation score 3 0.05 0.00
Peak aortic jet velocity, m/s 0.02 0.01
Valvuloarterial impedance, mm Hg/ml/m2.04 0.22 0.00
 Values are standardized raw-score regression coefﬁcients  SE. *Adjusted for
impedance on univariate analysis as well as other clinically relevant variables (
Abbreviations as in Table 1.pecified exclusion criterion in the ASTRONOMERrial, the results and conclusions of this substudy
an be applied only to patients with no clinical
ndication for lipid-lowering therapy with a statin.
Myocardial strain was not measured in the
STRONOMER study. Follow-up data of systolic
nd diastolic mitral annulus velocities by Doppler
issue imaging were available only in a small pro-
ortion of patients included in this study. Hence,
he impact of insulin resistance on the progression
f LV dysfunction could not be assessed.
C O N C L U S I O N S
Insulin resistance was a powerful and independent
predictor of progression of LVH and global hemody-
namic burden in these patients with AS. The effect of
insulin resistance on LVH progression persisted after
adjustment for AS severity, global LV hemodynamic
load, and their progression during follow-up. The
metabolic abnormalities linked to visceral obesity and,
in particular, insulin resistance may thus present novel
therapeutic targets in AS.
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